Soligenix Achieves Orphan Drug Status in Europe for SGX945 to Combat Behçet's Disease Soligenix has been granted orphan drug status in Europe for SGX945, aimed at treating Behçet's Disease, significantly advancing treatment options for patients.

Soligenix Achieves Orphan Drug Status in Europe for SGX945 to Combat Behçet's Disease #United_States #Princeton #Soligenix #SGX945 #Behçet's

Soligenix's SGX945 Receives UK's Promising Innovative Medicine Designation for Behçet's Disease Soligenix, Inc. has received the Promising Innovative Medicine designation from the UK authorities for their innovative treatment, SGX945, targeting Behçet's Disease.

Soligenix's SGX945 Receives UK's Promising Innovative Medicine Designation for Behçet's Disease #United_States #Princeton #Soligenix #SGX945 #Behçet's_Disease

Soligenix Gains EMA's Favor for Orphan Drug Status for SGX945 in Behçet's Disease Treatment Soligenix has successfully received a positive recommendation from the EMA for SGX945's orphan drug designation targeting Behçet's Disease, showcasing promising clinical results.

Soligenix Gains EMA's Favor for Orphan Drug Status for SGX945 in Behçet's Disease Treatment #United_States #Princeton #Soligenix #SGX945 #Behçet's_Disease

Soligenix's 2026 Outlook: Progress, Innovations, and Future Prospects in Rare Disease Treatments Soligenix, Inc. shares its 2026 roadmap detailing significant clinical milestones in rare disease therapies and expected market opportunities.

Soligenix's 2026 Outlook: Progress, Innovations, and Future Prospects in Rare Disease Treatments #USA #Princeton #Soligenix #HyBryte #SGX945

Promising Phase 2 Trial Results for SGX945 in Treating Behçet's Disease Indicate Durable Relief New findings from Soligenix reveal SGX945 shows significant potential in treating Behçet's Disease, offering hope for improved quality of life.

Promising Phase 2 Trial Results for SGX945 in Treating Behçet's Disease Indicate Durable Relief #USA #Princeton #Soligenix #SGX945 #Behçet's_Disease

Soligenix Announces Promising Phase 2 Results for SGX945 in Behçet's Disease Treatment Soligenix's Phase 2 trial of SGX945 shows significant efficacy in treating Behçet's Disease, paving the way for further exploration and reformulation.

Soligenix Announces Promising Phase 2 Results for SGX945 in Behçet's Disease Treatment #United_States #Princeton #Soligenix #SGX945 #Behçet's_Disease